A Phase Ib/II, Open-label, Multi-center Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Capmatinib (Primary) ; PDR 001 (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 17 Mar 2017 Planned End Date changed from 3 Apr 2019 to 24 Dec 2018.
- 28 Feb 2017 Planned primary completion date changed from 1 Apr 2019 to 24 Dec 2018.